StockData
Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc. (ABOS) company profile

ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 2/30
$0.23+0.01 (+6.53%)

Close on Nov 17, 2026Market cap $16.64MP/E –Yield –

About Acumen Pharmaceuticals

Biological Products, (No Diagnostic Substances), SIC 2836

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted disease-modifying therapies for Alzheimer’s disease. Its lead product candidate, sabirnetug (ACU193), is a recombinant humanized monoclonal antibody designed to selectively bind and neutralize soluble amyloid-beta oligomers, which are neurotoxic assemblies implicated in synaptic dysfunction and neurodegeneration. In addition to sabirnetug, the company is advancing blood-brain barrier-penetrating enhanced brain delivery therapies for Alzheimer’s pathology. As a clinical-stage enterprise, its candidates target individuals diagnosed with early Alzheimer’s disease, encompassing those with mild cognitive impairment or mild dementia associated with amyloid pathology.

The company operates without internal commercial manufacturing, storage, or distribution facilities, relying instead on specialized contract manufacturers to supply drug substances, drug products, and raw materials for clinical programs. The provided text discusses clinical operations within the United States but does not state the company's headquarters location or full operational scale.

Summary of the business section of Acumen Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Acumen Pharmaceuticals, Inc.
Headquarters
Newton, MA
Address
1210-1220 Washington Street, Suite 210 02465
Phone
(617) 344-4190
Employees
61, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
ABOS
Exchange
Nasdaq
IPO date
Jul 2, 2021
Shares outstanding
72M, Oct 21, 2026
Public float
$45.30M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1576885
CUSIP
00509G209
ISIN
US00509G2093
FIGI
BBG0058YJ317
Share class FIGI
BBG0058YJ326
EIN
36-4108129

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Daniel Joseph OConnellChief Executive Officer, Director881,275
Derek M. MeisnerChief Legal Officer & Corp Sec173,999
Eric SiemersChief Medical Officer255,371
Russell BartonChief Operating Officer205,092
Matt ZugaCFO & Chief Business Officer304,924
James J. DohertyPresident and CDO220,900
Amy SchacterleChief Regulatory Officer92,303
Derrell PorterDirector48,540
Nathan B. FountainDirector48,150
Kimberlee C. DrapkinDirector48,300
John A. Stalfort IIIDirector352,219
Rajeev M. ShahDirector19,103,785
Peter KolchinskyDirector–
Ra Capital Management, L.P.Director13,043,179
RA Capital Nexus Fund II, L.P.Director48,300
Laura StoppelDirector48,300
George GolumbeskiDirector35,500
Jeffrey L. IvesDirector48,300
Capital Healthcare Fund LP RADirector12,800

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Daniel O’Connell
Chief Executive Officer
$646.35K$412.48K$478.34K$305.73K$20.67K$1.86M-61%
Matthew Zuga
Chief Financial Officer and Chief Business Officer
$486.99K$123.58K$143.43K$172.98K$21.81K$948.79K-44%
Jim Doherty
President and Chief Development Officer
$520.00K$115.07K$133.42K$223.60K$20.77K$1.01M-54%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 2, 2021
Offer price
$16.00
Securities offered
9,999,999
Gross proceeds
$160.00M
Exchange
Nasdaq
First trading day
Jul 1, 2021
First-day close
$20.10+25.6%
Lock-up ends (est.)
Dec 28, 2021

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 25, 2026, we had 61 employees, 60 of which were full time.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?